sorafenib has been researched along with Epithelial Ovarian Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Y; Fu, Y; Guo, G; Guo, W; Hou, H; Huang, C; Jiang, C; Kuang, Y; Li, H; Li, X; Mu, M; Tong, A; Wang, J; Wang, Y; Wang, Z; Xu, J; Yang, C; Yang, H; Zhang, Z; Zhao, S; Zhou, L | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC | 1 |
| Bodnar, L; Górnas, M; Szczylik, C | 1 |
3 trial(s) available for sorafenib and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2011 |
1 other study(ies) available for sorafenib and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Topics: Animals; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; B7 Antigens; Carcinoma, Ovarian Epithelial; CD3 Complex; Cell Line, Tumor; Cell Proliferation; Datasets as Topic; Drug Synergism; Female; HEK293 Cells; Humans; Kaplan-Meier Estimate; Lymphocytes, Tumor-Infiltrating; Mice; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Sorafenib; T-Lymphocytes; Xenograft Model Antitumor Assays | 2020 |